Myo-inositol for PCOS: what the research actually shows

Of everyone who reaches a supplement page for PCOS, the myo-inositol group is unusual: they already know the ingredient’s name. They have read about it on forums, or their gynaecologist mentioned it, or a friend with the same diagnosis recommended it. They are not looking to be told it exists, they want to know what it does, at what dose, and whether the version in front of them is the right one.

This article is written for that reader. It covers what the research examined, what the 40:1 ratio means, the practical dose problem nobody mentions on a label, and where the evidence genuinely runs out.

This is information for people making decisions about products, not medical advice. PCOS is a diagnosed condition that needs proper clinical care. Nothing here is a substitute for your own doctor.

What inositol is

Inositol is a sugar alcohol that the body makes and that also occurs in food, fruit, beans, grains and nuts. It is not an exotic botanical; it is a compound involved in ordinary cell signalling.

Two forms matter in this conversation:

Myo-inositol (MI) is the most abundant form in the body and the one most studied in the PCOS context.

D-chiro-inositol (DCI) is produced from myo-inositol by an enzyme, and is present in much smaller quantities in most tissues.

The reason both appear on labels is the ratio question, which we will get to.

Why it is discussed in PCOS at all

PCOS is closely associated with insulin signalling. A large share of people with the diagnosis have some degree of insulin resistance, independent of body weight, and that connection is central to how the condition is now understood clinically.

Inositols are involved in the cellular machinery downstream of the insulin receptor. That is the mechanistic reason researchers began looking at them in PCOS, rather than it being a traditional remedy that was later rationalised.

A reasonable body of trials has examined myo-inositol supplementation in women with PCOS, looking at outcomes including insulin markers, cycle regularity, androgen markers and, in fertility settings, ovulation and oocyte quality. Several systematic reviews have pooled these.

What the research supports, and how to read that carefully

Here is where honesty matters more than enthusiasm.

The general picture. Across trials, myo-inositol supplementation has been associated with improvements in metabolic and some hormonal markers in women with PCOS, and in fertility settings with ovulation measures. Reviews have generally been cautiously positive.

The caveats that any fair summary has to include. Many individual trials are small. Study designs, doses, durations and the specific PCOS phenotypes included vary a great deal, which makes pooling awkward. Some comparisons are against metformin rather than against placebo, which answers a different question. And publication in this area is uneven.

What this means for you as a reader. The evidence is genuinely more substantial than it is for most things sold for PCOS, that is a real distinction and worth knowing. It is not the same as a settled, high-certainty clinical conclusion. Anyone presenting it as the latter is overselling.

The 40:1 ratio, explained

You will see “40:1 myo-inositol to D-chiro-inositol” on better-informed products. The number comes from the approximate physiological ratio of the two forms in plasma, and from trial work suggesting that this combination performed comparably to or better than myo-inositol alone in some settings.

In practice:

• A 40:1 product delivers 40 parts myo-inositol to 1 part D-chiro-inositol
• At the commonly studied daily intake, that works out to roughly 2,000 mg MI with 50 mg DCI, taken twice daily in many protocols
• D-chiro-inositol is substantially more expensive than myo-inositol, which is why plenty of products quietly leave it out

Whether the ratio matters more than simply taking enough myo-inositol is still debated. What is clear is that a product claiming a 40:1 ratio should state both quantities.

The dose problem nobody puts on the front of the pack

This is the single most useful practical thing in this article.

The intakes used in research are typically in the range of 2 to 4 grams of myo-inositol per day. Grams, not milligrams.

Now look at a tablet. A 1,000 mg tablet containing 250 mg of myo-inositol alongside other herbs delivers a quarter of a gram. To reach 2 grams you would need eight tablets a day.

This is not a criticism of combination tablets, they have a different job, which is to pair a recognised nutrient with a classical herbal base in a convenient daily format, and plenty of customers want exactly that. But if your reason for buying is specifically to replicate the research intake, a tablet will not get you there.

What does: a powder or sachet format, where 2 grams is a measured scoop rather than a handful of tablets. If someone is pointing you at research doses, that is the format that matches.

We make both, and we would rather say this plainly than let a customer assume a tablet is doing something it cannot.

What a product may and may not claim

If you are evaluating products, this section tells you which labels to distrust.

In India, a myo-inositol supplement may reasonably speak to women’s reproductive wellness, cycle support and metabolic wellness, and may describe the traditional use of any herbs included. What it may not do:

• Claim to treat, cure or reverse PCOS
• Claim to regulate or restore menstruation
• Claim to make someone conceive
• Promise a specific timeline or outcome

These are medicinal claims. They breach Indian advertising rules, and in our own manufacturing we decline artwork that makes them. If a product you are looking at makes them, treat its other statements with the same scepticism.

Where the classical herbs fit

Indian PCOS products often combine myo-inositol with kanchnar, shatavari, daruharidra and methi. There is a sensible reason for this and a commercial one, and both are worth naming.

The sensible reason: these herbs have a long traditional record in stri-roga and in glandular formulations, and methi contributes fibre, which is relevant to the metabolic side of the picture.

The commercial reason: the nutrient wins the customer who researched the condition, and the classical base earns trust with the family members who often influence the purchase. That is a real dynamic in Indian households and it is not dishonest to design for it, provided neither half of the label overclaims.

What we would not do is present the herbal component as though it has the same evidence base as the inositol. It does not, and saying so costs nothing.

Practical notes if you decide to try it

• Give it time. Trials generally run three to six months. Judging it in three weeks will tell you nothing.
• Dose matters more than brand. If you are aiming at the research intake, check the quantity per serving rather than the price.
• Tell your doctor. Particularly if you take metformin or any hormonal medication, not because of a known serious interaction, but because they should know what you are taking.
• It is not a lifestyle substitute. The clinical consensus on PCOS management puts diet, movement and sleep at the centre. Inositol is discussed as an adjunct, and anyone selling it as a replacement is misleading you.
• Side effects are usually mild. Digestive upset at higher intakes is the most commonly reported. It is generally well tolerated.

What we would like to see change in this category

Two things, said as a manufacturer.

First, more products stating the actual myo-inositol quantity prominently rather than burying it in a composition panel nobody reads. The number is the product.

Second, less shame in the marketing. PCOS content in India, particularly in Hindi, is frequently framed around weight, appearance and marriageability in a way that is both unkind and commercially short-sighted. The audience is young, well informed and talks to each other. Brands that treat them as adults build something durable; brands that trade on anxiety do not.

The short version

Myo-inositol has a more substantial evidence base in PCOS than almost anything else sold for it, and that base is still not conclusive. Research intakes are 2–4 grams a day, which a tablet cannot deliver, check the quantity, and use a powder if the dose is your reason for buying. The 40:1 ratio is worth looking for but should be stated in full. Give it months, not weeks. And treat any product claiming to cure PCOS as one that is lying about other things too.

For composition and sourcing detail, see Ovario 360. For the broader claims position, our label compliance guide sets out what can and cannot be printed.